As per our report, the Asia Pacific Contraceptives Market size was worth USD 5.37 billion in 2020 and estimated to reach USD 7.52 billion by the end of 2025, with a growing potential of 6.95%.
The main factors leading to the growth of the contraceptive and device market in the Asia-Pacific region include avoiding unnecessary pregnancy and its complications. The need to prevent unintended pregnancy, especially among teenage girls, is one of the main driving forces of the market. It has also been observed that more than half of women believe that the use of non-contraceptive pills is good for health, such as treating menstrual periods, menstrual pain, and acne. It is also one of the factors contributing to market growth.
The increasing incidence of sexually transmitted diseases and the rapid increase in the population are lucratively elevating the demand of the APAC Contraceptives Market. Government initiatives are also one of the factors fueling the need for the market.
The related risks associated with, social and cultural impacts of contraceptives and infertility caused by contraceptives are significant obstacles to APAC Contraceptives Market growth.
The spread of sexually transmitted diseases and increasing population control leads to the demand in the market. The Asia-Pacific contraceptive market is estimated to grow at a profitable rate during the forecast period. The implementation of measures aimed at reducing unintended pregnancies related to health care costs and the subsequent increase in user awareness is creating opportunities in the market.
The availability of alternative contraceptive methods is the main challenge in the APAC Contraceptives Market.
This research report on the APAC Contraceptives Market has been segmented & sub-segmented into the following categories:
By Drug Type:
By Medical Devices:
By End User:
By Country:
Geographically, Asia Pacific was profoundly influencing the industry in terms of demographics and lack of awareness within the large population. Favorable government initiatives about sex education are one of the major factors expected to boost the contraceptives market growth over the forecast period.
Notable companies dominating the APAC contraceptives market are Bayer HealthCare AG, Teva Pharmaceutical Industries Limited, Medisafe Distribution Inc, Pace Pharmaceuticals Inc., Medicines360, Church & Dwight, Co., Inc., Actavis, Inc., CooperSurgical, Inc., Merck & Co., Inc., Reckitt Benckiser plc, Mayer Laboratories, Inc., and Pfizer, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug type
5.1.1 Contraceptive pills
5.1.2 Topical contraceptives
5.1.3 Contraceptive injectable
5.1.4 Others (contraceptive gels, jellies and creams)
5.2 By Medical Devices
5.2.1 Male contraceptive devices
5.2.2 Female contraceptive devices
5.2.2.1 Female condoms
5.2.2.2 Intrauterine devices
5.2.2.3 Contraceptive sponges
5.2.2.4 Contraceptive diaphragms
5.2.2.5 Contraceptive patches
5.2.2.6 Subdermal contraceptive implants
5.2.2.7 Non-surgical permanent contraceptive devices
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Bayer HealthCare AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Teva Pharmaceutical Industries Limited
8.3 Medisafe Distribution Inc
8.4 Pace Pharmaceuticals Inc
8.5 Medicines360
8.6 Church & Dwight, Co., Inc.
8.7 Actavis, Inc
8.8 CooperSurgical
8.9 Merck & Co., Inc
8.10 Reckitt Benckiser plc
8.11 Mayer Laboratories, Inc
8.12 Pfizer, Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market outlook and Investment oppurtunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
